Immunomedics Expands Clinical Collaboration With Astrazeneca to Include Metastatic Non-Small Cell Lung Cancer
November 07, 2018 16:00 ET
|
Immunomedics
Phase 2 Platform Study to Evaluate the Combination of Imfinzi® (Durvalumab) and Sacituzumab Govitecan in Patients with Non-Small Cell Lung Cancer Who Progressed on or after Immune Checkpoint Inhibitor...
Immunomedics to Report First Quarter Fiscal 2019 Results and Host Conference Call and Webcast on November 7, 2018
October 31, 2018 08:00 ET
|
Immunomedics
MORRIS PLAINS, N.J., Oct. 31, 2018 (GLOBE NEWSWIRE) -- Immunomedics, Inc., (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug...
Immunomedics and Samsung BioLogics Announce Strategic Manufacturing Partnership
September 12, 2018 08:00 ET
|
Immunomedics
MORRIS PLAINS, N.J. and INCHEON, South Korea, Sept. 12, 2018 (GLOBE NEWSWIRE) -- Immunomedics, Inc., (NASDAQ: IMMU) and Samsung BioLogics Co., Ltd. today announced the companies have entered into a...
Immunomedics Announces Participation in Upcoming Healthcare Conferences
August 28, 2018 08:00 ET
|
Immunomedics
MORRIS PLAINS, N.J., Aug. 28, 2018 (GLOBE NEWSWIRE) -- Immunomedics, Inc., (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug...
Immunomedics Announces Fourth Quarter and Fiscal Year 2018 Results and Provides Corporate Update
August 23, 2018 16:00 ET
|
Immunomedics
Biologics License Application (BLA) Accepted for Filing and Granted Priority Review by the U.S. Food and Drug Administration (FDA) U.S. Commercial Launch Preparations on Track Lifecycle Management...
Immunomedics to Report Fourth Quarter and Fiscal Year 2018 Results and Host Conference Call and Webcast on August 23, 2018
August 16, 2018 16:35 ET
|
Immunomedics
MORRIS PLAINS, N.J., Aug. 16, 2018 (GLOBE NEWSWIRE) -- Immunomedics, Inc., (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug...
Immunomedics Announces Multiple Clinical and Preclinical Collaborations With Prominent Cancer Research Institutions
July 30, 2018 08:00 ET
|
Immunomedics
Clinical Collaboration with Yale University to Evaluate Sacituzumab Govitecan in Two Phase 2 Studies in Endometrial and Cervical Cancers Research Collaborations with Yale University, Memorial Sloan...
Immunomedics Announces Clinical Collaboration With AstraZeneca in First-Line Triple-Negative Breast and Urothelial Cancers
July 23, 2018 08:00 ET
|
Immunomedics
MORRIS PLAINS, N.J., July 23, 2018 (GLOBE NEWSWIRE) -- Immunomedics, Inc., (NASDAQ:IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug...
FDA Accepts Biologics License Application for Filing and Grants Priority Review for Sacituzumab Govitecan for the Treatment of Metastatic Triple-negative Breast Cancer
July 18, 2018 08:00 ET
|
Immunomedics
MORRIS PLAINS, N.J., July 18, 2018 (GLOBE NEWSWIRE) -- Immunomedics, Inc., (NASDAQ:IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug...
Immunomedics Announces Closing of Public Offering of Common Stock
June 15, 2018 11:39 ET
|
Immunomedics
MORRIS PLAINS, N.J., June 15, 2018 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (NASDAQ:IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug conjugates...